The pharmacokinetic profile of a new generation of parenteral cephalosporin

American Journal of Medicine

Volumn 100, Issue 6 A, 1996, Pages 39S-44S

  Rybak, Michael ^a  

^a DETROIT RECEIVING HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; CEFEPIME; CEPHALOSPORIN DERIVATIVE;

AGING; ANTIBIOTIC THERAPY; BACTERIAL PNEUMONIA; CHOLECYSTITIS; CLINICAL TRIAL; CONFERENCE PAPER; CYSTIC FIBROSIS; DOSE CALCULATION; DOSE KIDNEY FUNCTION RELATION; DOSE LIVER FUNCTION RELATION; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG DISPOSITION; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG SAFETY; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; KIDNEY FAILURE; LIVER FAILURE; PRIORITY JOURNAL; ADULT; AGED; FEMALE; HALF LIFE TIME; MALE; MIDDLE AGED; REVIEW; TIME; TISSUE DISTRIBUTION;

ADULT; AGED; AGED, 80 AND OVER; CEPHALOSPORINS; FEMALE; HALF-LIFE; HUMANS; MALE; MIDDLE AGED; TIME FACTORS; TISSUE DISTRIBUTION;

EID: 0030600045     PISSN: 00029343     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0002-9343(96)00106-4     Document Type: Conference Paper

References (29)

1. Sanders CC. Cefepime: The next generation? Clin Infect Dis. 1993;17:369-379.
2. Mandell GL, Petri WA Jr. Antimicrobial agents (continued): penicillins. cephalosporins, and other β-lactam antibiotics. In: Hardman JG, Goodman Gilman A, Limbird LE, eds. Goodman and Gilman's The Pharmacological Basis of Therapeutics, 9th ed. New York: McGraw-Hill, 1996:1073-1101.
3. Fung-Tomc J, Dougherty TJ, DeOrio FJ, Simich-Jacobson V, Kessler RE. Activity of cefepime against ceftazidime- and cefotaxime-resistant gram-negative bacteria and its relationship to β-lactamase levels. Antimicrob Agents Chemother. 1989;33:498-502.
4. Palmer SM, Kang SL, Cappelletty DM, Rybak MJ. Bactericidal killing activities of cefepime, ceftazidime, cefotaxime, and ceftriaxone against Staphylococcus aureus and β-lactamase-producing strains of Enterobacter, aerogenes and Klebsiella pneumoniae in an in vitro infection model. Antimicrob Agents Chemother. 1995;39:1764-1771.
5. McGrath BJ, Bailey EM, Lamp KC, Rybak MJ. Pharmacodynamics of once-daily amikacin in various combinations with cefepime, aztreonam, and ceftazidime against Pseudomonas aeruginosa in an in vitro infection model. Antimicrob Agents Chemother. 1992;36:2741-2746.
6. Fuchs PC, Jones RN, Barry AL, Thornsberry C. Evaluation of the in vitro activity of BMY-28142, a new broad-spectrum cephalosporin. Antimicrob Agents Chemother. 1985;27:679-682.
7. Thornsberry C, Brown SD, Yee YC, Bouchillon SK, Maler JK, Rich T. In-vitro activity of cefepime and other antimicrobials: survey of European isolates. J Antimicrob Chemother. 1993;32 (suppl B):31-53.
8. Liu Y-C, Huang W-K, Cheng D-L. Antibacterial activity of cefepime in vitro. Chemotherapy. 1994;40:384-390.
9. Barbhaiya RH, Forgue ST, Shyu WC, Papp EA, Pittman KA. High-pressure liquid chromatographic analysis of BMY-28142 in plasma and urine. Antimicrob Agents Chemother. 1987;31:55-59.
10. Barbhaiya RH, Forgue ST, Gleason CR, et al. Safety, tolerance, and pharmacokinetic evaluation of cefepime after administration of single intravenous doses. Antimicrob Agents Chemother. 1990;34:1118-1122.
11. Barbhaiya RH, Forgue ST, Gleason CR, et al. Pharmacokinetics of cefepime after single and multiple intravenous administrations in healthy subjects. Antimicrob Agents Chemother. 1992;36:552-557.
12. Barbhaiya RH, Knupp CA, Tenney J, Martin RR, Weidler DJ, Pittman KA. Safety, tolerance, and pharmacokinetics of cefepime administered intramuscularly to healthy subjects. J Clin Pharmacol. 1990;30:900-910.
13. Pfeffer M, Knupp CA. A safety and dose proportionality study of cefepime in normal, healthy male volunteers. Study No. AI411-155-001. Data on file, Bristol-Myers Squibb Pharmaceutical Research Institute, Wallingford, CT.
14. Kalman D, Barriere SL, Johnson BL Jr. Pharmacokinetic disposition and bactericidal activities of cefepime, ceftazidime, and cefoperazone in serum and blister fluid. Antimicrob Agents Chemother. 1992;36:453-457.
15. Nye KJ, Shi YG, Andrews JM, Wise R. Pharmacokinetics and tissue penetration of cefepime. J Antimicrob Chemother. 1989;24:23-28.
16. Chadha D, Wise R, Baldwin DR, Andrews JM, Ashby JP, Honeybourne D. Cefepime concentrations in bronchial mucosa and serum following a 2 gram intravenous dose. J Antimicrob Chemother. 1990;25:959-963.
17. Okamoto MP, Chin A, Gill MA, et al. Analysis of cefepime tissue penetration into human appendix. Pharmacotherapy. 1991;11:353-358.
18. Pfeffer M, Knupp CA. Penetration of cefepime into human breast milk, a pharmacokinetic study. Data on file, Bristol-Myers Squibb Co. Pharmaceutical Research Institute, Wallingford, CT.
19. Kovarik J, Rozenberg-Arska M, Visser M, Verhoef J. Pharmacodynamics of cefepime. Scand J Infect Dis. 1991;74(suppl):270-273.
20. Barbhaiya RH, Knupp CA, Pfeffer M, Pittman K. Lack of pharmacokinetic interaction between cefepime and amikacin in humans. Antimicrob Agents Chemother. 1992;36:1382-1386.
21. Barbhaiya RH, Knupp CA, Pittman KA. Effects of age and gender on pharmacokinetics of cefepime. Antimicrob Agents Chemother. 1992;36:1181-1185.
22. Barbhaiya RH, Knupp CA, Forgue ST, Matzke GR, Guay DRP, Pittman KA. Pharmacokinetics of cefepime in subjects with renal insufficiency. Clin Pharmacol Ther. 1990;48:268-276.
23. Barbhaiya RH, Knupp CA, Forgue ST, et al. Disposition of the cephalosporin cefepime in normal and renally impaired subjects. Drug Metab Dispos. 1991;19:68-73.
24. Barbhaiya RH, Knupp CA, Pfeffer M, et al. Pharmacokinetics of cefepime in patients undergoing continuous ambulatory peritoneal dialysis. Antimicrob Agents Chemother. 1992;36:1387-1391.
25. Pfeffer M, Knupp CA. Pharmacokinetics of cefepime in normal and hepatically impaired male subjects. Data on file. Bristol-Myers Squibb Co. Pharmaceutical Research Institute, Wallingford, CT.
26. Kovarik JM, Ter Maaten JC, Rademaker CMA, et al. Pharmacokinetics of cefepime in patients with respiratory tract infections. Antimicrob Agents Chemother. 1990;34:1885-1888.
27. LeBel AM, Knupp CA, Manseau L, et al. Altered Pharmacokinetics of cefepime in cystic fibrosis. (Abstr. 962.) 32nd ICAAC Meeting, 1992.
28. Arguedas AG, Stutman HA, Zaleska M, et al. Cefepime: Pharmacokinetics and clinical response in patients with cystic fibrosis. Am J Dis Child. 1992;146:797-802.
29. Okamoto MP, Gill MA, Nakahiro RA, et al. Tissue concentrations of cefepime in acute cholecystitis patients. Ther Drug Monit. 1992;14:220-225.